Methods and Compositions for Inhibiting Tumor Cell Proliferation
The invention provides agents, compositions, pharmaceutical compositions and method for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell.
1 . A polypeptide that inhibits FoxM1B activity in a tumor cell, said polypeptide comprising (1) a p19Arf peptide fragment comprising p19Arf amino acid residues 26-44 of SEQ ID NO:16, and (2) an HIV Tat peptide of SEQ ID NO:17 or a nine-D-Arg peptide of SEQ ID NO:18 that is covalently linked to the N-terminus of the p19Arf peptide fragment, wherein the polypeptide is modified at the N-terminus, at the C-terminus or at both the N terminus and the C terminus.
2 . The polypeptide of claim 1 wherein the modified polypeptide has the amino acid sequence of SEQ ID NO:19.
3 . The polypeptide according to claim 1 , wherein the N terminus is modified by acetylation.
4 . The polypeptide of claim 3 wherein the C terminus is modified by amidation.
5 . The polypeptide according to claim 1 wherein the C terminus is modified by amidation.
6 . The polypeptide of claim 3 wherein the C terminus is modified by acetylation.
7 . The polypeptide of claim 1 wherein the polypeptide is isolated.
8 . A pharmaceutical composition comprising the polypeptide of claim 1 , further comprising at least one pharmaceutically acceptable diluent, carrier or excipient.
9 . The pharmaceutical composition of claim 8 wherein the polypeptide has the amino acid sequence of SEQ ID NO:19.
10 . A method of inhibiting FoxM1 activity in a tumor cell comprising the step of contacting a cell that expresses FoxM1B with the polypeptide of claim 1 .
11 . The method of claim 10 wherein the modified polypeptide has the amino acid sequence of SEQ ID NO:19.
12 . The method of claim 10 , wherein the tumor cell is of epithelial origin.
13 . The method of claim 10 , wherein the tumor cell is a liver tumor cell.